tion. Motor and sensory examinations yielded normal findings. He reported no radicular pain, numbness, tingling, or weakness.
To evaluate his abdominal symptoms, a CT scan of the abdomen and pelvis was obtained. The internal organs were normal, but incidental hypodense lesions were seen in the sacrum and several vertebral bodies of the lumbar spine (Fig. 1) . Magnetic resonance imaging studies of the lumbosacral spine showed hypointense lesions on T1-weighted imaging that enhanced intensely after the administration of gadolinium and were hyperintense on T2-weighted MR imaging (Fig. 2) . The differential diagnosis at this time was infectious instead of congenital hemangiomas. On completion of a course of intravenous antibiotics, follow-up MR imaging studies showed progressive growth of these lesions. The differential diagnosis at this stage was a neoplastic (multiple myeloma, lymphoma) or infectious (tuberculosis, sarcoidosis, bacterial, fungal) process. A bone marrow biopsy was then performed and showed no evidence of disease.
Operation. A CT-guided needle biopsy initially performed on one of the sacral lesions yielded nondiagnostic results. The Neurosurgery Service was consulted for an open biopsy procedure that was performed on the right L-4 pedicle lesion.
Pathological Findings. The biopsy specimen showed fragments of bone and fibrous tissue that contained a tumor composed of a monomorphic proliferation of spindle cells forming small vessels with irregular contours. Endothelial proliferation was present (Fig. 3A) , and the tissue stained positive for HHV8 (Fig. 3B) .
Postoperative Course. The patient was hospitalized overnight and was discharged the following day on oral analgesics. In addition to the highly active antiretroviral therapy that he was taking previously, he was started on vincristine biweekly as recommended by the Oncology Service. Three months later, follow-up MR imaging showed minimal regression of the lesions. His viral load was still stable, and clinical examination showed that he had gained weight.
Discussion
Kaposi sarcoma is a mesenchymal tumor that was first described by Dr. Moritz Kaposi in 1872. It was considered a rare tumor of the skin until the HIV epidemic occurred, and the incidence of the disease increased strikingly in the immunocompromised population, with 15 to 20% of HIV- infected men developing KS. 1 Internal organs, particularly the gastrointestinal tract, lungs, and lymph nodes, have been reported as primary sites of KS. 4, 5 Spine involvement has been documented, and in fact, spinal decompression was performed to alleviate symptoms of spinal cord compression. 15 However, these lesions were a later manifestation after the initial appearance of the disease in different organs (Table 1) . 7, 8, 12, 15 The hallmark of KS is the characteristic skin lesion that is seen in most cases. It is unusual to see the clinical presentation of KS in the spine. In fact, when the disease first became more prevalent in HIV-infected patients, the literature seemed to indicate that KS was not a disease of the spine. 7 Vertebral lesions in a patient with cutaneous lesions seemed to support the differential diagnosis of bacillary angiomatosis over KS. 7 We now describe what we believe is the first reported case of KS in the spine without manifestation of the disease in the skin or in any other location such as the lungs or the gastrointestinal tract.
In recent years, it has been shown that HHV8 is necessary but not sufficient for the development of KS. In all likelihood, there are probably genetic and environmental factors in addition to HHV8 that cause KS. 6 An influential factor is the weakening of the immune system.
Treatment Modalities
Therapeutic modalities for KS depend on the extent of the disease. Highly active antiretroviral therapy is an effective prophylactic and therapeutic regimen for AIDS-related KS. 13 In cases of transplant-related KS, the recommended approach is modification of immunosuppressive regimens to the lowest dose consistent with graft function, with a response rate close to 50%. 2 Systemic chemotherapy is generally reserved for patients with visceral or progressive KS. A variety of therapeutic modalities has been used, including the administration of liposomal doxorubicin, liposomal danorubicin, vincristine, etoposide, cisplatin, interferon, vinblastine, bleomycin, paclitaxel, and bleomycin/vincristine in combination, with success rates between 59 and 88%. 2, 9 Localized and cutaneous lesions can be managed with local therapies such as radiotherapy, cryotherapy, cryosurgery, and laser surgery; however, radiotherapy has been related to an increased long-term risk of developing carcinomas. 9 
Natural Course
Regression has been observed in transplant-related KS after the dose of immunosuppressive treatment is lowered; it occurs spontaneously in 2 to 20% of classic KS cases and rarely in AIDS-related KS. 11 The latter disease regresses after effective highly active antiretroviral therapy or chemotherapy. The AIDS-related form of KS has been staged according to the AIDS Clinical Trials Group classification system, with recent modification since the use of highly antiretroviral therapy began. 10 Patients are usually classified as having good or poor risk based on their tumor burden, immune function as measured by CD4 T-lymphocyte count, and the presence of systemic illness. Multivariate analysis demonstrated that the combination of poor tumor stage and systemic disease identified patients with a poor prognosis, with a 3-year survival rate of 53%, compared with 80% in patients without this combination.
Conclusions
Kaposi sarcoma may not present with typical findings in HIV-positive patients. Our case of KS is exceptional because of its presentation as spine lesions alone. This case shows that lesions may occur without a cutaneous manifestation in an area not typically associated with the disease, and thus a diagnosis of KS cannot be ruled out by a rare location, specifically that of the spine. Thus, neurosurgeons need be aware of its presentation. Furthermore, it is important to take into account the risk factors associated with KS, which include but are not limited to the patient's HIV status, sex, sexual preference, and ethnicity. We suggest that the differential diagnosis of spine lesions in patients with HIV, even if there is no cutaneous manifestation, should include KS.
